230 related articles for article (PubMed ID: 20187092)
21. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Holmes JP; Clifton GT; Patil R; Benavides LC; Gates JD; Stojadinovic A; Mittendorf EA; Ponniah S; Peoples GE
Cancer; 2011 Feb; 117(3):463-71. PubMed ID: 20845479
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
23. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
24. Immunizing against breast cancer: a new swing for an old sword.
Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
[TBL] [Abstract][Full Text] [Related]
25. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
26. Roadmap to a better therapeutic tumor vaccine.
Emens LA
Int Rev Immunol; 2006; 25(5-6):415-43. PubMed ID: 17169782
[TBL] [Abstract][Full Text] [Related]
27. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
28. A comparison and critical analysis of preclinical anticancer vaccination strategies.
Kochenderfer JN; Gress RE
Exp Biol Med (Maywood); 2007 Oct; 232(9):1130-41. PubMed ID: 17895521
[TBL] [Abstract][Full Text] [Related]
29. [Peptide-based vaccine therapy for cancer patients].
Yamada A
Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
[No Abstract] [Full Text] [Related]
30. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Hos BJ; Tondini E; van Kasteren SI; Ossendorp F
Front Immunol; 2018; 9():884. PubMed ID: 29755468
[TBL] [Abstract][Full Text] [Related]
31. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker].
Hazama S; Maeda K; Oka M
Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395
[TBL] [Abstract][Full Text] [Related]
32. Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma.
Schlapbach C; Yerly D; Daubner B; Yawalkar N; Hunger RE
J Dermatol Sci; 2011 May; 62(2):75-83. PubMed ID: 21377838
[TBL] [Abstract][Full Text] [Related]
33. [Current status and prospects of cancer vaccine therapy].
Mine T; Terazaki Y; Itoh K
Nihon Rinsho; 2011 Sep; 69(9):1651-6. PubMed ID: 21922769
[TBL] [Abstract][Full Text] [Related]
34. Overcoming doubts and other obstacles in the development of effective peptide-based therapeutic vaccines against cancer.
Cho HI; Celis E
Expert Rev Vaccines; 2010 Apr; 9(4):343-5. PubMed ID: 20370542
[No Abstract] [Full Text] [Related]
35. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
36. Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A; Snyder A; Chan TA
Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
[TBL] [Abstract][Full Text] [Related]
37. [Development of next-generation peptide vaccination therapy].
Tsukahara T; Hirohashi Y; Emori M; Torigoe T
Nihon Rinsho; 2017 Feb; 75(2):270-274. PubMed ID: 30562863
[TBL] [Abstract][Full Text] [Related]
38. [Peptide vaccination for castration-resistant prostate cancer].
Koga N; Noguchi M
Nihon Rinsho; 2014 Dec; 72(12):2147-51. PubMed ID: 25518349
[TBL] [Abstract][Full Text] [Related]
39. Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine.
Probst P; Stringhini M; Ritz D; Fugmann T; Neri D
Clin Cancer Res; 2019 Jan; 25(2):698-709. PubMed ID: 30327303
[TBL] [Abstract][Full Text] [Related]
40. Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer.
Jacobs JJ; Snackey C; Geldof AA; Characiejus D; Van Moorselaar RJ; Den Otter W
Anticancer Res; 2014 Jun; 34(6):2689-700. PubMed ID: 24922629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
